ALMSAlumis Inc.
Alumis Inc. (ALMS) is a biopharmaceutical company focused on the development of oral therapies for chronic inflammatory diseases, including plaque psoriasis. The next catalyst is October 15, 2026 — Secondary Equity Offering, which will test the company’s ability to raise capital amid ongoing liquidity concerns and the pending Phase 3 envudeucitinib data. The offering’s success will hinge on investor confidence in the drug’s potential to capture market share in a crowded dermatology space.
- Alumis operates in a highly competitive pharmaceutical sector, where late-stage clinical data and regulatory outcomes drive valuation.
- The company has a history of mixed market reactions to its clinical milestones, with a notable surge following robust Phase 3 results in Q2 2026.
- The Secondary Equity Offering is a critical test of capital structure and market sentiment ahead of key regulatory and commercial events.
The Read
Alumis’s stock showed muted or slightly negative reactions around initial positive Phase 3 envudeucitinib data and NDA plans in March 2026, but surged about 19% after late-breaking robust clinical results at the AAD meeting in Q2 2026 overcame earlier liquidity concerns.
The schedule
- Thu15Oct
The secondary offering will test the market's appetite for dilutive equity and the company's ability to raise capital without significantly diluting existing shareholders.
- Mon16Nov
The release of interim clinical data will test the market's confidence in the company's drug development progress and its ability to meet regulatory milestones.
- Thu11Feb
This earnings report will provide a broader view of the company's financial health and operational performance, with a focus on its ability to sustain cash flow and meet its obligations.
- Mon10May
This earnings report will provide a comprehensive view of the company's financial performance and its ability to execute on its strategic initiatives.
- Mon9Aug
- Wed8Sep
Participation in the UPC event could provide visibility into the company's market position and potential partnerships, but the event's impact is likely to be limited due to the company's regulatory and legal risks.
- Mon8Nov
Past
- Thu13Aug
This earnings report will test the company's ability to maintain cash flow and manage its capital structure amid ongoing regulatory and legal scrutiny. The results will also provide insight into the progress of its clinical trials and the potential for near-term approvals.
- Thu14May
Actual outcome: Bear · $24.15 at outcome
The stock fell 2.1% from the event date to the outcome date, missing the bull target and falling short of the bear floor. The earnings report showed an EPS actual of -0.74, matching the estimate, but the key catalyst was the positive Phase 3 trial data for envudeucitinib in psoriasis, which was released after the earnings report. Despite the positive trial results, the stock declined, likely due to broader market sentiment and lack of immediate catalysts to drive a stronger rebound.
- Sun29Mar
Actual outcome: Bull · $22.73 at outcome
Alumis reported in-line earnings with an EPS of -$0.74, but the stock rallied 12.5% and exceeded the bull target due to highly positive clinical updates. The company presented late-breaking Phase 3 data for envudeucitinib at the AAD meeting demonstrating robust improvements in skin clearance and psoriasis symptoms, which overshadowed prior liquidity concerns and drove strong investor optimism.
Market focus will shift heavily toward Alumis's liquidity constraints as cash burn outpaces remaining reserves.